Radiometal complexes: Characterization and relevant in vitro studies

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 3, 2008, Pages 222-234

  Jurisson, S ^a   Cutler, C ^a   Smith, S V ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Metals; Radiochemistry; Radionuclide imaging

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ASCORBIC ACID; CARBON 11; COPPER 64; COPPER 67; COPPER COMPLEX; CYCLAM; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); FLUORINE 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; HOLMIUM; IODINE 123; IODINE 124; LANTHANIDE; LEXIDRONAM SAMARIUM SM 153; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MOLYBDENUM 99; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; RHENIUM COMPLEX; SAMARIUM 153; SELENOMETHIONINE; TEBOROXIME TC 99M; TECHNETIUM 99M; TECHNETIUM COMPLEX; TETROFOSMIN TC 99M; TRACER;

CHEMICAL STRUCTURE; CHROMATOGRAPHY; COMPLEX FORMATION; CONCENTRATION RESPONSE; DIAGNOSTIC IMAGING; DISSOCIATION; DRUG DESIGN; DRUG STABILITY; DRUG SYNTHESIS; HALF LIFE TIME; IN VITRO STUDY; ISOTOPE LABELING; NUCLEAR MEDICINE; OXIDATION REDUCTION REACTION; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING;

ANIMALS; COPPER; DRUG DESIGN; HUMANS; HYDROLYSIS; IONS; LANTHANOID SERIES ELEMENTS; MODELS, CHEMICAL; NITROGEN; OXYGEN; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TECHNETIUM; TIME FACTORS;

EID: 48749107462     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Jurisson S, Berning D, Jia W, Ma D. Coordination Compounds in Nuclear Medicine. Chem Rev 1993;93:1137-56.
2. Jurisson SS, Lydon JD. Potential Technetium Small Molecule Radiopharmaceuticals. Chem Rev 1999;99:2205-18.
3. Mallinckrodt. Material Safety Data Sheet. TecneScan MAG3®. Technetium Tc99m Mertiatide. [Internet]. [cited April 16, 2008]. Available from: http://www.imaging.mallinckrodt.com/_Attachments/MSDS/ TechneScan%20mag3.pdf
4. Shriver DF, Atkins P, Langford CH. Inorganic Chemistry. 2nd ed. New York: W. H. Freeman & Company; 1994. p. 212-5.
5. Roesch F. Radiolanthanides in endoradiotherapy: an overview. Radiochim Acta 2007;95:303-11.
6. Sekine T, Hasegawa Y. Solvent Extraction Chemistry: Fundamentals and Applications. New York: Marcel Dekker; 1977.
7. Rydberg J, Musikas C, Choppin GR. Principles and Practices of Solvent Extraction. New York: Marcel Dekker; 1992.
8. Ketring AR, Ehrhardt GJ, Embree MF, Bailey KD, Tyler TT, Gawenis JA et al. Production and Supply of High Specific Activity Radioisotopes for Radiotherapy Applications. J Alasbimn 5(19). http://www.alasbimnjournals.cl/revistas/19/ketring.html (January 2003).
9. 177Lu]Lu-AMBA, a systemic radiotherapeutic agent for gastrin releasing peptide receptor positive tumors. Appl Radiat Isot 2008; 66:497-505.
10. Holmes RA. [153Sm]EDTMP: a potential therapy for bone cancer. Semin Nucl Med 1992;22:41-5.
11. Faranghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451-8.
12. Bayouth JE, Macey DJ, Kasi LP, Garlich JR, McMillan K, Dimopoulos MA et al. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995;36:730-7.
13. Li WP, Ma DS, Higginbotham C, Hoffman T, Ketring AR, Cutler CS et al. Development of an in vitro model for assessing in vivo stability of lanthanide chelates. Nucl Med Biol 2001;28:145-54.
14. Volkert WA, Hoffman TJ. Therapeutic Radiopharmaceuticals. Chem Rev 1999;99:2269-92.
15. Stimmel JB, Kull FC Jr. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 1998;25:117-25.
16. Uger O, Kostakoglu L, Hui ET, Fisher DR, Garmestoni K, Gansow OA et al. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol 1996;23:1-8.
17. 177LuDOTMP-a new alternative to metastatic bone pain palliation? formulation studies. J Labelled Compd Radiopharm 2007;50:S276.
18. 177Lu-labeled DOTMP and EDTMP. J Labelled Compd Radiopharm 2007;50:S446.
19. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, jurisson SS, Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm 2000;15:531-45.
20. Smith SV. Molecular imaging with copper-64 in the drug discovery and development arena. Expert Opin Drug Discov 2007;2:659-72.
21. Smith SV. Molecular Imaging with Cu-64. J Inorg Biochem 2004;98:1874-901.
22. Barnard P, Bayly S, Betts H, Bonnitcha P, Christlieb M, Dilworth J et al. Towards new copper based radiopharmaceuticals. Q J Nucl Med Mol Imaging 2008;52:174.
23. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging 2008;52:185.
24. Smith SV. Sarar technology for the application of Copper-64 in biology and materials science. Q J Nucl Med Mol Imaging 2008;52:193.
25. 67Cu. Proc Natl Acad Sci USA 1996; 93:6814-8.
26. Tarkanyi F, Takacs S, Ditroi F, Hermanne A, Sonck M, Shubin Y. Excitation functions of deuteron induced nuclear reactions on natural zinc up to 50 MeV. Nucl Instrum Methods Phys Res B 2004;217:531-50.
27. Bonardi ML, Groppi F, Mainardi HS, Kokhanyuk VM, Lapshina EV, Mebel MV et al. Cross section studies on Cu-64 with zinc target in the proton energy range from 141 down to 31 Mev. J. Radioanalytical Nucl Chem 2005;264:101-5.
28. Szelecesnyi F, Steyn GF, Kovacs Z, Vermeulen C, van der Meulen NP, Dolley SG et al. Investigation of the Zn-66(p,2pn)Cu-64 and Zn-68 (p,x)Cu-64 nuclear processes up to 100 MeV: Production of Cu-64. Nucl Instrum Methods Phys Res B 2005;240:625-37.
29. Abbas K, Kozempel J, Bonardi M, Groppi F, Alfarano A, Holzwarth U et al. Cyclotron production of Cu-64 by deuteron irradiation of Zn-64. Appl Radiat Isot 2006;64:1001-5.
30. Al-Abyad M, Spahn I, Sudar S, Morsy M, Comsan MNH, Csikai J et al. Nuclear data for production of the therapeutic radionuclides P-32, Cu-64 Cu-67, Sr-89, Y-90 and Sm-153 via the (n,p) reaction: Evaluation of excitation function and its validation via integral cross-section measurement using a 14MeV d(Be) neutron source. Appl Radiat Isot 2006;64:717-24.
31. Tarkanyi F, Ditroi F, Csikai J, Takacs S, Uddin MS, Hagiwara M et al. Activation cross-sections of long-lived products of proton-induced nuclear reactions on zinc. Appl Radiat Isot 2005;62:73-81.
32. Abbasi IA, Zaidi JH, Arif A, Subhani MS. Measurement of fission neutron spectrum averaged cross sections of some threshold reactions on zinc: small-scale production of no-carrier-added Cu-64 in a nuclear reactor. Radiochim Acta 2006;94:63-7.
33. Hetherington EL, Sorby PJ, Carnakaris J. The preparation of high specific activity copper-64 for medical diagnosis. Appl Radiat Isot 1986;37:1242-3.
34. 67Ga Waste Products Using Anion Exchange and Low Acid Aqueous/ Organic Mixtures, Radiochim Acta 1996;75:65-8.
35. Smith SV. Challenges and opportunities for positron-emission tomography in personalized medicine. IDrugs 2005;8:827-33.
36. Ulrich C, Kruger B, Kohler H, Riegel W. Effects of Acidosis on Acute Phase Protein Metabolism in Liver Cells. Mineral Electrolyte Metab 1999;25:228-33.
37. Schreiber R, Zhang F, Haussinger D. Regulation of vesicular pH in liver macrophages and parenchymal cells by ammonia and anisotonicity as assessed by fluorescein isothiocyanate-dextram fluorescence. Biochem J 1996;315:385-92.
38. Sarka L, Buria L, Brucher E. The rates of the exchange reactions between [Gd(DTPA)](2-) and the endogenous ions Cu2+, and Zn2+: A kinetic model for the prediction of the in vivo stability of [Gd(DTPA)](2-) used as a contrast agent in magnetic resonance imaging. Chem Eur J 2000;6:719-24.
39. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC et al. [Cu-64-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007;104:12462-7.
40. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Design 2007;13:3-16.
41. Di Bartolo NM, Sargeson AM, Donlevy TM, Smith SV. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J Chem Soc (Dalton Transactions) 2001;15:2303-9.
42. 64Cu imaging agents for personalised medicine and drug development using the Hexa-Aza Cage, SarAr. Org Biomol Chem 2006;4:3350-7.
43. Voss SD, Smith SV, DiBartolo N, Mclntos LJ, Cyr EM, Bonab AA et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with Cu-64-SarAr immunoconjugates. Proc Natl Acad Sci U S A 2007;104:17489-93.